Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors



  ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board
  of Directors

Business Wire

SAN DIEGO -- January 22, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders,  today announced
the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr.
Biggar will fill a vacancy on ACADIA’s board and serve as a Class II director.
The terms of the Class II directors will expire at the annual meeting of
stockholders in 2015.

“This is a particularly exciting time to join the ACADIA board following the
highly successful results from the pivotal Phase III Parkinson’s disease
psychosis trial with pimavanserin,” said Dr. Biggar. “I share in ACADIA’s
enthusiasm and belief that pimavanserin has the potential to transform the
treatment landscape for patients suffering from this serious disorder and may
also offer an improved therapy option for a broader range of neuropsychiatric
disorders. Following the recent financing, which raised $86 million, ACADIA
has a solid foundation for building the full potential of pimavanserin. I look
forward to being a part of the ACADIA team as we work to develop and
commercialize pimavanserin and other potential new drugs that may improve the
lives of patients.”

Dr. Biggar serves as a Partner at Baker Brothers Investments, a fund
management company focused on long-term investments in life-sciences
companies. From April 2002 to October 2006, he served as a Principal with
Baker Brothers Investments which he had joined as an Associate in April 2000.
Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in
Immunology from Stanford University and received a B.S. in Genetics from the
University of Rochester. Dr. Biggar also serves as a director for Synageva
BioPharma Corp., a publicly traded biotechnology company.

“We are delighted that Steve has joined ACADIA’s board,” said Uli Hacksell,
Ph.D., ACADIA’s Chief Executive Officer. “His extensive experience as an
investor in a wide range of biotechnology companies together with his medical
and scientific training will provide our board with a unique perspective and
enhance our collective experience.”

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
advanced preclinical programs directed at Parkinson’s disease and other
neurological disorders. All product candidates are small molecules that
emanate from discoveries made at ACADIA. ACADIA maintains a website at
www.acadia-pharm.com to which ACADIA regularly posts copies of its press
releases as well as additional information and through which interested
parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the progress and timing of ACADIA’s drug discovery
and development programs, either alone or with a partner, and the clinical
benefits to be derived from ACADIA’s product candidates, in each case
including pimavanserin. In particular, forward-looking statements include
statements regarding the impact of ACADIA’s recent financing and the potential
for pimavanserin to transform the treatment landscape for Parkinson’s disease
psychosis and to be an improved therapy for a broader range of
neuropsychiatric disorders. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that past
results of clinical trials may not be indicative of future trial results. For
a discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December 31, 2011 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this cautionary
statement and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except as
required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Uli Hacksell, Ph.D., Chief Executive Officer
Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief
Business Officer
858-558-2871
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement